Drugs / GR1802
Trials 9
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 25 trials | ||||||
| Phase 2 | NCT06315426 | Mar 2024 → May 2025 overdue | seasonal allergic rhinitis | Genrix (Shanghai) Biopharmaceutical Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06028490 | Sep → Nov 2023 | allergic rhinitis | Zheng Liu ENT | Unknown | No outcome recorded |
| Phase 2 | NCT06015243 | Aug 2023 → Dec 2024 | chronic rhinosinusitis | Genrix (Shanghai) Biopharmaceutical Co., Ltd. | Unknown | No outcome recorded |
| Phase 2 | NCT05873803 | Feb 2023 → Oct 2024 | chronic rhinosinusitis | Genrix (Shanghai) Biopharmaceutical Co., Ltd. | Unknown | No outcome recorded |
| Phase 2 | NCT06642961 | Jul 2022 → Mar 2025 | asthma | Genrix (Shanghai) Biopharmaceutical Co., Ltd. | Unknown | No outcome recorded |
| Phase 34 trials | ||||||
| Phase 3 | NCT07199257 | Sep 2025 → May 2027 expected | seasonal allergic rhinitis | Genrix (Shanghai) Biopharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07154342 | Aug 2025 → Apr 2026 overdue | seasonal allergic rhinitis | Genrix (Shanghai) Biopharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT06516302 | Sep 2024 → Mar 2026 overdue | chronic rhinosinusitis | Genrix (Shanghai) Biopharmaceutical Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06216392 | Jan 2024 → Jun 2025 | atopic eczema | Genrix (Shanghai) Biopharmaceutical Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GR1802 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06642961 ↗ |
| Action | Inhibit | “anti-IL4Rα” NCT06315426 ↗ |
| Modality | Monoclonal antibody | “Recombinant fully human anti-IL4Rα monoclonal antibody drug.” NCT06028490 ↗ |
| Route | Subcutaneous | “Route of administration: Subcutaneous” NCT05873803 ↗ |
| Target | IL4R | “anti-IL4Rα monoclonal antibody drug” NCT06315426 ↗ |